Navigation Links
Amsterdam Molecular Therapeutics Reports Full Year Results 2009
Date:2/24/2010

AMSTERDAM, February 24, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year to December 31, 2009.

    Highlights
    - Glybera(R) Marketing Authorisation Application submitted to
      European Medicines Agency (EMA, formerly known as EMEA);
    - EMA commenced formal review of Glybera(R) dossier on January
      20, 2010;
    - EMA grants orphan drug designation for AMT's Acute
      Intermittent Porphyria ("AIP") program;
    - EMA grants orphan drug designation for AMT's Duchenne
      Muscular Dystrophy ("DMD") program;
    - SenterNovem awards EUR 4 million investment credit for the
      development of AMT's DMD program;
    - Raised EUR 5 million convertible loan notes, which convert
      into ordinary shares at EUR 3.91 per share;
    - New management team.

Jorn Aldag, Chief Executive Officer of AMT, commented: "In 2009 we announced a rebalancing of our strategy, focused on our lead product Glybera(R), a proprietary product for lipoprotein lipase deficiency (LPLD), together with the ongoing development of four earlier stage progams targeting:
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
3. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
5. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
6. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
7. Amsterdam Molecular Therapeutics Part of Next Biotech Index
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
11. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized ... October 29-30 in San Francisco, CA. This year’s conference ... researchers and clinicians focused on addressing and solving the ... the twelve years since the sequencing of the human ... with pharmacogenetic information in the label and molecular diagnostics ...
(Date:8/20/2014)... improve the health of your heart, researchers have discovered. ... a standard TENS machine like those designed to relieve ... the small raised flap at the front of the ... The stimulation changed the influence of the nervous system ... can drive failing hearts too hard. , Professor Jim ...
(Date:8/19/2014)... Piscataway, NJ (PRWEB) August 20, 2014 ... engineering and regenerative medicine is an inadequate vascular ... engineered constructs and decellularized tissues is critical for ... Researchers have attempted to mitigate deficiencies in vascularization ... including adding scaffold bioactivity, optimizing scaffold design and ...
(Date:8/19/2014)... , Aug. 19, 2014 A Geisinger ... been nominated for a Centers for Disease Control and ... a major public health concern. Joseph ... is one of a team of researchers nominated for ... C. Shepard Science Award for Data Methods and Study ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... , , , ... the Sciences in Education over the Next Decade , WASHINGTON, Dec. ... continuously published magazine in the U.S., hosted The Decade-2 ... to promote the teaching of math and science to America,s students and was ...
... , , PROVIDENCE, R.I., Dec. 9 The ... disease (AD), which was conducted at 30 sites around the ... Neurology®. Lead author, Stephen P. Salloway, MD, MS, director ... professor of neurology and psychiatry at the Warren Alpert Medical ...
... , SAN DIEGO, Dec. 9 Sangart, Inc., a ... designed to enhance the perfusion and oxygenation of ischemic ... delivery, today announced that the European Commission (EC) has ... treatment of sickle cell disease. This designation provides ten ...
Cached Biology Technology:Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 2Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 3Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3
(Date:8/21/2014)... have developed a novel and versatile modeling strategy to ... new materials as well as for studying polyelectrolytes, including ... to model much larger and more complex polyelectrolyte systems, ... Li, lead author of a paper on the work ... Materials Science and Engineering. "This is a big step ...
(Date:8/20/2014)... a John and Rebecca Moores Professor of Biology and Biochemistry ... in the International Society for the Study of the Origin ... members two from the U.S., one from France and ... are elected every three years, and 36 have been named ... 20 countries, the ISSOL includes researchers from disciplines as varied ...
(Date:8/20/2014)... LAKE CITY Researchers at Huntsman Cancer Institute (HCI) at ... forms of the gene that encodes BCR-ABL, the unregulated ... According to the American Cancer Society, nearly 6,000 new ... Drugs already in use, called tyrosine kinase inhibitors (TKIs), ... They do not cure CML but control it in ...
Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2UH professor named fellow by International Astrobiology Society 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... cause poor lung development in children, making them more vulnerable ... in life, say researchers at the University of Pittsburgh Graduate ... Environmental Health. Their study, published online in Physiological Genomics ... in both mouse lungs and children ages 9 to 11. ...
... with the flu virus, we have investigated how the ... of the Experimental Mouse Genetics research group. In infection ... immune response is responsible for the fatal outcome of ... The findings have now been published in the scientific ...
... 2009 A material developed at the Hebrew University ... tissue) following surgery has led to approval by the ... for use in pediatric cardiac surgery patients. ... invention of novel, tailor-made, biodegradable polymers for the prevention ...
Cached Biology News:Changes in gene may stunt lung development in children 2The host makes all the difference 2Hebrew University professor's work leads to FDA approval for product 2
... (RNase III) from E. coli is an ... to dsRNA fragments that have 2-base, 3'-overhangs. ... dsRNA fragments of 12-15 bp. RNase ... canonical ribonucleotides as well as DuraScript™ RNA, ...
...
...
... to CRF The antibody ... CRF sequence that it was ... are found in the paraventricular ... in colchicine treated 4% FA ...
Biology Products: